<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02452060</url>
  </required_header>
  <id_info>
    <org_study_id>14-00472</org_study_id>
    <nct_id>NCT02452060</nct_id>
  </id_info>
  <brief_title>Study on the Use of Low Dose Ketamine After Gastric Bypass and Gastrectomy</brief_title>
  <official_title>Randomized, Double-blind, Placebo Controlled Study on the Effect of a Single Postoperative Administration of Low Dose Ketamine After Gastric Bypass and Gastrectomy Surgeries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, two-arm parallel, single-center
      study. One hundred subjects (50 in each arm) will be enrolled. Subjects, between the ages 18
      and 65, undergoing laparoscopic gastric bypass or sleeve gastrectomy will be recruited and
      consented during the preadmission visit prior to surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, two-arm parallel, single-center
      study. One hundred subjects (50 in each arm) will be enrolled. Subjects, between the ages 18
      and 65, undergoing laparoscopic gastric bypass or sleeve gastrectomy will be recruited and
      consented during the preadmission visit prior to surgery. Eligible subjects will be
      randomized to one of the two treatment group in a 1:1 ratio to receive either IV ketamine
      (0.4mg/kg) or matching placebo. Both men and women will be recruited, and there is no
      limitation as to racial and ethnic origin. In the PACU, patients will receive either 0.4mg/kg
      IV ketamine or placebo. All patients will also receive standard post-anesthetic monitoring
      and care, as well as routine care after transfer out of the PACU. Patients are followed until
      the date of discharge, and endpoints (see below) are collected from patient reports as well
      as from medical charts. During their hospital stay (and once after their discharge from the
      hospital), patients will fill out five questionnaires which provide estimates of their
      postoperative pain control, mood and function, and quality of postsurgical recovery. An
      additional component of the study, which is entirely optional, is to obtain patient serum
      samples (about two teaspoons) in the operating room and 15 minutes and 4 hours after ketamine
      infusion. The investigators will use these samples to assess levels of IL-1, IL-6, TNF-α, and
      BDNF, which are markers for pain. In addition, with patient consent, the investigators will
      also store serum samples for future research use to measure other cytokines and neurotrophic
      factors and molecular markers associated with pain and depression.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2014</start_date>
  <completion_date type="Actual">April 13, 2017</completion_date>
  <primary_completion_date type="Actual">April 13, 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pain Scores</measure>
    <time_frame>Baseline (DOS) to 7 days (Post Op)</time_frame>
    <description>VAS Scores will be assessed on Day of Surgery (DOS), Post-op Day (POD) 1, 2 and 7. If patients have been discharged, coordinators will contact patient by home.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of Stay During Hospitalization</measure>
    <time_frame>8 days</time_frame>
    <description>LOS will be recorded from medical record.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Opioid Usage Per Hour During the PACU Stay Before and After Ketamine Infusion</measure>
    <time_frame>8 Days</time_frame>
    <description>Length of stay and opioid usage will be recorded from electronic medical chart</description>
  </other_outcome>
  <other_outcome>
    <measure>Opioid Usage Per Day Throughout the Hospital Stay</measure>
    <time_frame>8 days</time_frame>
    <description>recorded from medical chart</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to Out of Bed to Chair (OOB)</measure>
    <time_frame>7 Days</time_frame>
    <description>Patient will be asked to record and report the time to OOB</description>
  </other_outcome>
  <other_outcome>
    <measure>Spirometry Use 4 Hours After the Termination of Ketamine Infusion</measure>
    <time_frame>1 day</time_frame>
    <description>Spirometry use will be assessed by a study team member to determine whether the patient is meeting the goal set by the surgical team 4 hours after ketamine infusion.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Serum Level of IL-1 After Ketamine Infusion</measure>
    <time_frame>1 day</time_frame>
    <description>changes in serum levels of IL-1, which will be collected at baseline (in the OR preoperatively), and 15 min and 4 hours after the termination of ketamine infusion.</description>
  </other_outcome>
  <other_outcome>
    <measure>Survey Scores - McGill's Short Form</measure>
    <time_frame>Pre-op,Day of Surgery through Post-op Day 8</time_frame>
    <description>Change in survey scores -- McGill's short form</description>
  </other_outcome>
  <other_outcome>
    <measure>Survey Scores - Becks Depression Index (BDI)</measure>
    <time_frame>Pre-op,Day of Surgery through Post-op Day 8</time_frame>
    <description>Change in survey scores for Becks Depression Index (BDI)</description>
  </other_outcome>
  <other_outcome>
    <measure>Survey Scores - QoR15</measure>
    <time_frame>Pre-op,Day of Surgery through Post-op Day 8</time_frame>
    <description>Change in scores for Quality of Recovery 15 - QoR15</description>
  </other_outcome>
  <other_outcome>
    <measure>Survey Scores - MADRS</measure>
    <time_frame>Pre-op,Day of Surgery through Post-op Day 8</time_frame>
    <description>Change in scores for MADRS</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Serum Level of IL-6 After Ketamine Infusion</measure>
    <time_frame>1 day</time_frame>
    <description>changes in serum levels of IL-1, which will be collected at baseline (in the OR preoperatively), and 15 min and 4 hours after the termination of ketamine infusion.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Serum Level of TNF-α After Ketamine Infusion</measure>
    <time_frame>1 day</time_frame>
    <description>changes in serum levels of IL-1, which will be collected at baseline (in the OR preoperatively), and 15 min and 4 hours after the termination of ketamine infusion.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Serum Level of BDNF After Ketamine Infusion</measure>
    <time_frame>1 day</time_frame>
    <description>changes in serum levels of IL-1, which will be collected at baseline (in the OR preoperatively), and 15 min and 4 hours after the termination of ketamine infusion.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Pain</condition>
  <condition>Postoperative Depression</condition>
  <arm_group>
    <arm_group_label>treatment/placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>saline infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ketamine (0.4mg/kg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>0.4mg/kg infusion</description>
    <arm_group_label>treatment</arm_group_label>
    <other_name>ketalar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>0.4mg/kg infusion</description>
    <arm_group_label>treatment/placebo</arm_group_label>
    <other_name>Saline Infusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults, &gt;18 years, &lt;65 years, who will undergo gastric bypass or sleeve gastrectomy.

          2. Subject is non-lactating and is either:

               -  Not of childbearing potential; or

               -  Of childbearing potential but is not pregnant at time of baseline as determined
                  by pre-operative pregnancy testing.

          3. Subject is ASA physical status 1, 2, or 3.

          4. Subject who is deemed medically stable

        Exclusion Criteria:

          1. &lt;18 years of age; &gt;65 years of age

          2. Pregnant or breastfeeding

          3. Does not speak or understand English (the study forms used are copy-righted in
             English)

          4. Cognitively impairment (by history) or clinical signs of altered mental status

          5. History of misuse or abuse of ketamine

          6. History of chest pain or chest pain in the PACU

          7. Use of a medication that interferes with metabolism of ketamine within the last 24
             hours

          8. A diagnosis of schizophrenia and/ or a history of chronic antipsychotic medication use

          9. History of head trauma

         10. History of intracranial mass or hemorrhage

         11. History of stroke

         12. History of cardiac arrhythmia

         13. Subject for whom ketamine is contraindicated

         14. Unwillingness to give informed consent according to HIC guidelines
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing Wang, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 16, 2015</study_first_submitted>
  <study_first_submitted_qc>May 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2015</study_first_posted>
  <results_first_submitted>July 12, 2019</results_first_submitted>
  <results_first_submitted_qc>March 2, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 16, 2020</results_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>perioperative period</keyword>
  <keyword>pain</keyword>
  <keyword>gastric bypass</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT02452060/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment/Placebo</title>
          <description>saline infusion
Placebo Comparator: 0.4mg/kg infusion</description>
        </group>
        <group group_id="P2">
          <title>Treatment</title>
          <description>ketamine (0.4mg/kg)
Ketamine: 0.4mg/kg infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo Comparator: 0.4mg/kg saline infusion</description>
        </group>
        <group group_id="B2">
          <title>Ketamine</title>
          <description>Ketamine: 0.4mg/kg infusion</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Pain Scores</title>
        <description>VAS Scores will be assessed on Day of Surgery (DOS), Post-op Day (POD) 1, 2 and 7. If patients have been discharged, coordinators will contact patient by home.</description>
        <time_frame>Baseline (DOS) to 7 days (Post Op)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment/Placebo</title>
            <description>saline infusion
Placebo Comparator: 0.4mg/kg infusion</description>
          </group>
          <group group_id="O2">
            <title>Treatment</title>
            <description>ketamine (0.4mg/kg)
Ketamine: 0.4mg/kg infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain Scores</title>
          <description>VAS Scores will be assessed on Day of Surgery (DOS), Post-op Day (POD) 1, 2 and 7. If patients have been discharged, coordinators will contact patient by home.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" spread=".23"/>
                    <measurement group_id="O2" value="1" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Stay During Hospitalization</title>
        <description>LOS will be recorded from medical record.</description>
        <time_frame>8 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment/Placebo</title>
            <description>saline infusion
Placebo Comparator: 0.4mg/kg infusion</description>
          </group>
          <group group_id="O2">
            <title>Treatment</title>
            <description>ketamine (0.4mg/kg)
Ketamine: 0.4mg/kg infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Stay During Hospitalization</title>
          <description>LOS will be recorded from medical record.</description>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="1" upper_limit="2"/>
                    <measurement group_id="O2" value="1.2" lower_limit="1" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Opioid Usage Per Hour During the PACU Stay Before and After Ketamine Infusion</title>
        <description>Length of stay and opioid usage will be recorded from electronic medical chart</description>
        <time_frame>8 Days</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Opioid Usage Per Day Throughout the Hospital Stay</title>
        <description>recorded from medical chart</description>
        <time_frame>8 days</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time to Out of Bed to Chair (OOB)</title>
        <description>Patient will be asked to record and report the time to OOB</description>
        <time_frame>7 Days</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Spirometry Use 4 Hours After the Termination of Ketamine Infusion</title>
        <description>Spirometry use will be assessed by a study team member to determine whether the patient is meeting the goal set by the surgical team 4 hours after ketamine infusion.</description>
        <time_frame>1 day</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Serum Level of IL-1 After Ketamine Infusion</title>
        <description>changes in serum levels of IL-1, which will be collected at baseline (in the OR preoperatively), and 15 min and 4 hours after the termination of ketamine infusion.</description>
        <time_frame>1 day</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Survey Scores - McGill's Short Form</title>
        <description>Change in survey scores -- McGill's short form</description>
        <time_frame>Pre-op,Day of Surgery through Post-op Day 8</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Survey Scores - Becks Depression Index (BDI)</title>
        <description>Change in survey scores for Becks Depression Index (BDI)</description>
        <time_frame>Pre-op,Day of Surgery through Post-op Day 8</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Survey Scores - QoR15</title>
        <description>Change in scores for Quality of Recovery 15 - QoR15</description>
        <time_frame>Pre-op,Day of Surgery through Post-op Day 8</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Survey Scores - MADRS</title>
        <description>Change in scores for MADRS</description>
        <time_frame>Pre-op,Day of Surgery through Post-op Day 8</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Serum Level of IL-6 After Ketamine Infusion</title>
        <description>changes in serum levels of IL-1, which will be collected at baseline (in the OR preoperatively), and 15 min and 4 hours after the termination of ketamine infusion.</description>
        <time_frame>1 day</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Serum Level of TNF-α After Ketamine Infusion</title>
        <description>changes in serum levels of IL-1, which will be collected at baseline (in the OR preoperatively), and 15 min and 4 hours after the termination of ketamine infusion.</description>
        <time_frame>1 day</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Serum Level of BDNF After Ketamine Infusion</title>
        <description>changes in serum levels of IL-1, which will be collected at baseline (in the OR preoperatively), and 15 min and 4 hours after the termination of ketamine infusion.</description>
        <time_frame>1 day</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 Year</time_frame>
      <desc>0</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment/Placebo</title>
          <description>saline infusion
Placebo Comparator: 0.4mg/kg infusion</description>
        </group>
        <group group_id="E2">
          <title>Treatment</title>
          <description>ketamine (0.4mg/kg)
Ketamine: 0.4mg/kg infusion</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness/lightheadedness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>euphoria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Dysphoria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>visual hallucination</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jing Wang</name_or_title>
      <organization>NYU Langone Medical Center</organization>
      <phone>212-460-0176</phone>
      <email>jing.wang@nyulangone.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

